Literature DB >> 30422179

Relapses After CAR-T Therapy.

Jennifer Abbasi.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30422179     DOI： 10.1001/jama.2018.17585

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy.

Authors:  Kai Wang; Yu Zhao; Xuan Wang; Bin Wang; Maoquan Qin; Guanghua Zhu; Huantong Wu; Zhongfeng Liu; Xueling Zheng; Huyong Zheng; Zhiguo Chen
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

2.  Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy.

Authors:  Yu Zhao; Jianping Zhang; Junfang Yang; Huantong Wu; Yao Chen; Nannan Li; Zhongfeng Liu; Xuan Wang; Weihua Liu; Guangji Zhang; Bin-Bing Stephen Zhou; Peihua Lu; Zhiguo Chen
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.